Intelligence · Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.
-
BLEOPRIM 15 mg polvere per soluzione iniettabile, Fluorouracil 50 mg/ml Solution for Injection or Infusion, LEDERFOLIN 25 mg Polvere per soluzione iniettabile per uso endovenoso, CAMPTO 20 mg/mL concentrate for solution for infusion, Oxaliplatin 5 mg/ml Concentrate for Solution for infusion
Fondazione Telethon ETS
Locally Advanced Pancreatic Cancer
1 trial -
BMS-986466
Bristol-Myers Squibb
Advanced Solid Tumors
1 trial -
BMS-986517
Bristol-Myers Squibb Australia Pty Ltd
Advanced Solid Tumors
1 trial -
BMS-986523, BMS-986523
Bristol-Myers Squibb Australia Pty Ltd
Advanced Solid Tumor Malignancies
1 trial -
BNT116
Regeneron UK Limited
Advanced Non-Small Cell Lung Cancer
1 trial -
BNT116, LIBTAYO 350 mg concentrate for solution for infusion.
Lacuna Pharma Pty Ltd
Advanced Non-Small Cell Lung Cancer
1 trial -
BNT327 1-15, BNT327, BNT326
BioNTech SE
Advanced solid tumors
1 trial -
BNT327 50 mg ml, BNT327 20 mg ml, IPILIMUMAB, ATEZOLIZUMAB, ATEZOLIZUMAB, BEVACIZUMAB, Ipilimumab
Bristol-Myers Squibb Australia Pty Ltd
Advanced or unresectable Hepatocellular Carcinoma (HCC)
1 trial -
BNT327, BNT323
BioNTech SE
Advanced Breast Cancer Metastatic Breast Cancer
1 trial -
BNT327, BNT324
BioNTech SE
Advanced Lung Cancer
1 trial -
BNT329
BioNTech SE
Advanced Solid Cancers
1 trial -
BT1718
BICYCLE THERAPEUTICS
Advanced Solid Tumours
1 trial -
BT8009, Zelenectide Pevedotin
BICYCLE THERAPEUTICS
NECTIN4 Amplified Advanced Breast Cancer
1 trial -
BT8009, Zelenectide Pevedotin, PEMBROLIZUMAB
BICYCLE THERAPEUTICS
Nectin-4 Expressing Advanced Malignancies.
1 trial -
Bavencio 20 mg/mL concentrate for solution for infusion
Disc Medicine
locally advanced urothelial cancer.
1 trial -
Belzutifan, PALBOCICLIB
Merck Sharp and Dohme
Advanced ccRCC
1 trial -
Bevacizumab combined with Oxaliplatin and TAS-102
The First People's Hospital of Lianyungang
Advanced Colorectal Cancer
1 trial -
Binimetinib
United Therapeutics Europe Ltd
Locally Advanced Pancreatic Carcinoma
1 trial -
Brigatinib
Takeda
ALK-positive Advanced NSCLC
2 trials -
Budenofalk 3mg magensaftresistente Hartkapseln, ALIMTA 100 mg powder for concentrate for solution for infusion, KEYTRUDA 25 mg/mL concentrate for solution for infusion., CISPLATINE ACCORD 1 mg/ml, solution à diluer pour perfusion, Carboplatin-GRY® 10 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Cisplatin NeoCorp 1 mg/ml - Konzentrat zur Herstellung einer Infusionslösung, Pemetrexed Accord 25 mg/ml concentrate for solution for infusion, Cisplatin Teva® 1 mg/ml Konzentrat zur Herstellung einer Infu
Hoffmann-La Roche
Untreated Advanced or Metastatic Non-Small Cell Lung Cancer
1 trial -
Budigalimab, Telisotuzumab adizutecan, Cisplatin 1mg/ml Injection BP, Carboplatin 10 mg/ml Intravenous Infusion, KEYTRUDA 25 mg/mL concentrate for solution for infusion, ALIMTA 500 mg powder for concentrate for solution for infusion
AbbVie Deutschland GmbH & Co. KG
Advanced or Metastatic Non-Squamous NSCLC
1 trial -
CABOMETYX 40 mg film-coated tablets, CABOMETYX 20 mg film-coated tablets, KEYTRUDA 25 mg/mL concentrate for solution for infusion
The George Institute
Advanced /metastatic sarcomas: undifferentiated pleomorphic sarcoma, osteosarcoma and Ewing sarcoma.
1 trial -
CABOMETYX 60 mg film-coated tablets, CABOMETYX 40 mg film-coated tablets, CABOMETYX 20 mg film-coated tablets
Ipsen
Unresectable, Locally Advanced or Metastatic Renal Cell Carcinoma with a Clear-Cell Component Who Progressed After 1st Line Treatment with Checkpoint Inhibitors
1 trial -
CALCIUM FOLINATE, ivonescimab, CALCIUM LEVOFOLINATE, OXALIPLATIN, FLUOROURACIL
Ningbo Cancer Hospital
Advanced biliary tract cancer (BTC)
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources